Instituto de Bioquímica Aplicada, Facultad de Bioquímica, Química y Farmacia, Universidad Nacional de Tucumán, Tucumán, Argentina.
Instituto de Biotecnología Farmacéutica y Alimentaria (INBIOFAL), Consejo Nacional de Investigaciones Científicas y Tecnològicas (CONICET), Universidad Nacional de Tucumán, San Miguel de Tucumán, Tucumán, Argentina.
Hemoglobin. 2020 Mar;44(2):122-127. doi: 10.1080/03630269.2020.1765794. Epub 2020 May 25.
β-Thalassemia (β-thal) trait is a heterogeneous group of genetic defects leading to decreased β-globin production, ineffective erythropoiesis, and oxidative stress. The aim is to evaluate the cytoprotective response, at transcriptional and systemic levels, of the variations of global redox balance in β-thal trait patients. Sixty-six subjects (40 healthy and 26 with β-thal trait) were analyzed at the Universidad Nacional de Tucumán, Tucumán, Argentina, between 2016 and 2017. The following parameters were evaluated: complete blood count, iron status, hemoglobin (Hb) electrophoresis, Hb A, thiobarbituric acid reactive species (TBARS), serum catalase (CAT), and superoxide dismutase (SOD) activity, , , , , , interleukin-6 (), and tumor necrosis factor-α () gene expression. The β-thal trait group showed a decrease in Hb levels, MCV, and MCH with higher TBARS levels. The SOD activity was significantly increased by 32.0% in β-thal trait patients respect to the control group. Relative expression of was 4.7-fold higher in β-thal trait than in the control group, while expression was similar in both groups. The , , and proinflammatory cytokines transcriptional expression was significantly upregulated in β-thal trait patients. This is the first study on the genetic regulation of redox balance in β-thal trait patients in which interesting modifications were observed in the transcript levels of some redox regulators that could be associated with changes in the erythrocyte proteome in this disorder. A better understanding of the pathophysiological mechanisms present in these heterozygous patients would allow adequate therapy in situations such as growth, pregnancy, or high performance sports, favoring a personalized treatment.
β-地中海贫血(β-thal)是一组导致β-球蛋白产生减少、无效红细胞生成和氧化应激的遗传缺陷。目的是评估β-地中海贫血患者的全球氧化还原平衡变化的转录和系统水平的细胞保护反应。2016 年至 2017 年期间,在阿根廷图库曼国立大学分析了 66 名受试者(40 名健康人和 26 名β-地中海贫血患者)。评估了以下参数:全血细胞计数、铁状态、血红蛋白(Hb)电泳、Hb A、硫代巴比妥酸反应性物质(TBARS)、血清过氧化氢酶(CAT)和超氧化物歧化酶(SOD)活性、白细胞介素-6()和肿瘤坏死因子-α()基因表达。β-地中海贫血组的 Hb 水平、MCV 和 MCH 降低,TBARS 水平升高。β-地中海贫血患者的 SOD 活性比对照组高 32.0%。与对照组相比,β-地中海贫血组的相对表达增加了 4.7 倍,而两组的表达相似。β-地中海贫血患者的、和促炎细胞因子的转录表达明显上调。这是第一项关于β-地中海贫血患者氧化还原平衡遗传调节的研究,在该研究中观察到一些氧化还原调节剂的转录水平发生了有趣的变化,这可能与该疾病中红细胞蛋白质组的变化有关。更好地了解这些杂合子患者中存在的病理生理机制将允许在生长、妊娠或高性能运动等情况下进行适当的治疗,从而促进个体化治疗。